A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity.

Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-83. PubMed PMID: 6133297.

Prevalence and correlates of diabetes in national schizophrenia samples.

Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26(4):903-12. PubMed PMID: 11087022.

Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.

van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 2008;10(2):342-8. DOI: 10.1111/j.1399-5618.2007.00520.x. PubMed PMID: 18271914.

Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.

Suvisaari J, Perälä J, Saarni SI, Härkänen T, Pirkola S, Joukamaa M, et al.. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur Arch Psychiatry Clin Neurosci. 2008;258(3):129-36. DOI: 10.1007/s00406-007-0762-y. PubMed PMID: 17990051.

Serious cardiovascular events and mortality among patients with schizophrenia.

Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 2004;192(1):19-27. DOI: 10.1097/01.nmd.0000105996.62105.07. PubMed PMID: 14718772.

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. AJP. 2003;160(2):284-9. DOI: 10.1176/appi.ajp.160.2.284. PubMed PMID: 12562574.

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.

Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. AJP. 2002;159(6):1055-7. DOI: 10.1176/appi.ajp.159.6.1055. PubMed PMID: 12042200.

The unhealthy lifestyle of people with schizophrenia.

Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29(3):697-701. PubMed PMID: 10405091.

Mortality in a cohort of patients with schizophrenia: a record linkage study.

Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991;36(4):239-45. PubMed PMID: 1868416.

A retrospective chart review of the clinical effects of atypical antipsychotic drugs on glycemic control in institutionalized patients with schizophrenia and comorbid diabetes mellitus.

Krosnick A, Wilson MG. A retrospective chart review of the clinical effects of atypical antipsychotic drugs on glycemic control in institutionalized patients with schizophrenia and comorbid diabetes mellitus. Clin Ther. 2005;27(3):320-6. DOI: 10.1016/j.clinthera.2005.02.017. PubMed PMID: 15878385.